PLGA nanoparticles, 100nm
Based on 1 Customer Validation
PLGA nanoparticles, 100nm, are biodegradable tumor-targeting nanocarriers that can serve as drug delivery enhancers and multidrug resistance inhibitors. PLGA nanoparticles, 100nm, passively enriched through the EPR effect and actively targeted via ligand-mediated endocytosis, can encapsulate various antitumor active molecules. PLGA nanoparticles, 100nm can specifically recognize multiple types of tumor cells and improve cellular uptake, cytotoxicity and antiproliferative effects after modification with ligands such as transferrin, folic acid, and RGD. PLGA nanoparticles, 100nm can encapsulate various therapeutic drugs and can be surface modified to achieve targeting, imaging, and prolonged circulation time, making them suitable for cancer-related research.
For research use only. We do not sell to patients.
-
Storage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
Biological Activity
PLGA nanoparticles, 100nm loaded with Dexamethasone (HY-14648) completely inhibit the proliferation of vascular smooth muscle cells[2].
PLGA nanoparticles, 100nm can deliver various active substances including p53 plasmids, Curcumin (HY-N0005), cysteine protease inhibitors, Camptothecin (HY-16560), Doxorubicin (HY-15142A), Paclitaxel (HY-B0015), Cisplatin (HY-17394), and Rapamycin (HY-10219), enhance drug accumulation in multiple tumor and smooth muscle cells, and prolong the duration of action[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
Appearance Solid
-
SMILES
CC(C)C(OCC(OC)=O)=O.[x].[y]
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Purity & Documentation
-
Data Sheet (270 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
[1].
Acharya S, Sahoo SK. PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect. Adv Drug Deliv Rev. 2011 Mar 18;63(3):170-83.
[Content Brief]
[2]. Costa MP, et al. Exploring the Potential of PLGA Nanoparticles for Enhancing Pulmonary Drug Delivery. Mol Pharm. 2025;22(7):3542-3562. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)